Thursday, November 19, 2026 Updated Briefings Saved 中文
AI Daily Radar

AI and the frontier tech around it, explained every morning

Demonstrated

Helus Pharma's HLP003 shows Phase 3 depression benefit, with safety questions

Photo: stevepb / Pixabay

Helus Pharma said Monday that its psychedelic drug candidate HLP003 significantly reduced depression scores in a Phase 3 trial, but the study also recorded a number of serious adverse events, which the company has not detailed publicly. Patients stayed on their standard antidepressants and received one dose of HLP003 on day one and a second three weeks later. At six weeks, the treatment group’s score on the MADRS depression scale fell 19.5 points versus 11.9 points for placebo; at 12 weeks the reductions were 16.9 and 9.9 points, and the company says all differences between groups were statistically significant. The figures come from a company announcement, not a peer-reviewed paper or a regulator’s review, so the size, cause and frequency of the serious adverse events remain unknown.

Verified and unconfirmed

  • Verified: Helus Pharma announced topline results from a Phase 3 trial of HLP003, given as two doses three weeks apart on top of participants’ existing antidepressants; per the company’s statement reported by STAT, the drug group’s MADRS depression score fell 19.5 points at six weeks versus 11.9 for placebo, and 16.9 versus 9.9 at 12 weeks, with the between-group differences statistically significant. Helus also disclosed that the study included a number of serious adverse events.
  • Not yet confirmed: how many serious adverse events occurred, what they were, and whether they were judged related to HLP003; the full safety and efficacy dataset, which has not been peer-reviewed or published, and any regulator’s view of it; and the eventual filing and approval timeline for HLP003.

Background

HLP003 is Helus Pharma’s oral, chemically modified version of psilocybin, which the company describes as a new chemical entity and which holds FDA Breakthrough Therapy Designation for use as an adjunct to standard antidepressants in major depressive disorder — a status meant to speed review of drugs showing early promise over existing options. It is being tested in Helus’s Phase 3 PARADIGM program; the company had said topline data from one of those studies, APPROACH, was expected in the fourth quarter of 2026.

Why it matters

The placebo-adjusted benefit was about 7.6 MADRS points at six weeks and 7.0 at 12 weeks — a real but moderate gap — so the deciding factor for patients and clinicians is likely to be the safety record rather than the efficacy signal. Until the serious adverse events are enumerated, doctors cannot weigh the two doses against existing antidepressants, and anyone tracking the drug should treat the efficacy numbers as provisional company-reported results.

What to watch

Watch for the full trial data, including the number and nature of the serious adverse events and the breakdown by treatment arm, to appear in a peer-reviewed publication or conference presentation, and for any regulatory submission Helus files.

Further reading

Comments

Comments

Comments use a GitHub account and are moderated. Comment rules

More in Science & Biotech

See all